Preclinical to Clinical Translation of Pharmacokinetic-Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors.
Saved in:
| Title: | Preclinical to Clinical Translation of Pharmacokinetic-Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors. |
|---|---|
| Authors: | Savoca A; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca (United Kingdom), Cambridge, United Kingdom., Zindel D; Mechanistic Biology and Profiling, Discovery Sciences, R&D, AstraZeneca (United Kingdom), Cambridge, United Kingdom., Polanski R; AstraZeneca Pharma Poland Sp. z o.o., R&D, Warsaw Clinical Operational Hub, Warsaw, Poland., Kostomiris DH; Mechanistic and Structural Biology, Discovery Sciences, R&D, AstraZeneca (United States), Waltham, Massachusetts., Pirmoradian M; Biomarker, Discovery and Development, Translational Science and Experimental Medicine, R&D, AstraZeneca, Gothenburg, Sweden., Swaih AM; Bioscience, Oncology OTD, AstraZeneca (United Kingdom), Cambridge, United Kingdom., Talbot S; Bioscience, Oncology OTD, AstraZeneca (United Kingdom), Cambridge, United Kingdom., Floc'h N; Bioscience, Oncology OTD, AstraZeneca (United Kingdom), Cambridge, United Kingdom., Winlow P; Mechanistic Biology and Profiling, Discovery Sciences, R&D, AstraZeneca (United Kingdom), Cambridge, United Kingdom., Davey PRJ; Chemistry, Oncology OTD AstraZeneca (United Kingdom), Cambridge, United Kingdom., Longmire D; Chemistry, Oncology OTD AstraZeneca (United Kingdom), Cambridge, United Kingdom., Wadforth E; Chemistry, Oncology OTD AstraZeneca (United Kingdom), Cambridge, United Kingdom., Lewis HJ; Bioscience, Oncology OTD, AstraZeneca (United Kingdom), Cambridge, United Kingdom., Smith A; Oncology DMPK, Oncology OTD, AstraZeneca (United Kingdom), Cambridge, United Kingdom., Lipka R; Oncology DMPK, Oncology OTD, AstraZeneca (United Kingdom), Cambridge, United Kingdom., Wilson J; Oncology DMPK, Oncology OTD, AstraZeneca (United Kingdom), Cambridge, United Kingdom., Britton DJ; Kinomica Ltd, Macclesfield, United Kingdom., Dokal AD; Kinomica Ltd, Macclesfield, United Kingdom., Smith R; Kinomica Ltd, Macclesfield, United Kingdom., Thomson C; Chemistry, Oncology OTD AstraZeneca (United Kingdom), Cambridge, United Kingdom., McCoull W; Chemistry, Oncology OTD AstraZeneca (United Kingdom), Cambridge, United Kingdom. |
| Source: | Molecular cancer therapeutics [Mol Cancer Ther] 2026 Jul 02; Vol. 25 (7), pp. 1157-1167. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
